Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysis
Top Cited Papers
- 28 May 2014
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 16 (10), 984-993
- https://doi.org/10.1111/dom.12307
Abstract
AimTo assess the efficacy and safety of the novel sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin compared with placebo or other antidiabetic agents in patients with type 2 diabetes. MethodsWe conducted a systematic review and meta-analysis of randomized controlled trials. We searched Medline, Embase and the Cochrane Library through December 2013 and grey literature. Two reviewers working independently extracted relevant data and carried out risk-of-bias assessments. We synthesized results using random-effects models and computed weighted mean differences (WMDs) and odds ratios (ORs). ResultsWe included 10 studies with 6203 participants. Compared with placebo, mean changes in haemoglobin A1c were -0.62% [95% confidence interval (CI) -0.68 to -0.57%] for empagliflozin 10 mg and -0.66% (-0.76 to -0.57%) for empagliflozin 25 mg. Empagliflozin 25 mg daily had glycaemic efficacy similar to metformin or sitagliptin (WMD -0.11%; 95% CI -0.25 to 0.03%), without increasing risk for hypoglycaemia. It was also associated with body weight loss (WMD -1.84; 95% CI -2.30 to -1.38 kg vs. placebo) and had a favourable effect on blood pressure. Incidence of hypoglycaemia with empagliflozin was similar to placebo (OR 1.10; 95% CI 0.87 to 1.39); nevertheless we noted an increased risk for genital tract infections (OR 3.31; 95% CI 1.55 to 7.09). Findings were similar for the 10-mg dosing regimen. ConclusionsEmpagliflozin effectively lowers blood glucose and provides additional clinical benefits including body weight and blood pressure reduction. Ongoing trials will elucidate the long-term safety and effect of empagliflozin on cardiovascular outcomes.This publication has 32 references indexed in Scilit:
- Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trialsBMC Endocrine Disorders, 2013
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseDiabetes, Obesity and Metabolism, 2013
- Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic controlCardiovascular Diabetology, 2013
- Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetesBMJ Open, 2012
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on MetforminJournal of Clinical Endocrinology & Metabolism, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trialsAnnals of Medicine, 2011
- Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetesDiabetes and Vascular Disease Research, 2008
- Quantifying heterogeneity in a meta-analysisStatistics in Medicine, 2002
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986